Procedure description

Project leader Universitat Politècnica de València (UPV)

The objective here, is to to set up use cases on the use of in-silico models for the simulation of drug efficacy, safety and cardiotoxicity.

Models for drug-ion channel interaction will be developed taking into consideration the plasmatic concentrations derived from pharmacokinetic and pharmacodynamic studies.

The models will be used to analyse the effects of drugs at a multi-scale level from cell to organ, in normal and pathological conditions, such as ischemia, heart failure or atrial fibrillation. Personalised models will be built according to the standardisation process, as well as populations of models where variability will be taken into account. Differences in gender and age will also be considered. Specific biomarkers to assess drug efficacy and safety will be defined.

The receiver operating characteristic curve biomarkers @UPV

Course of action

  1. Development of drug ion channel interaction models and assess drug effects at the cellular level in healthy and pathological virtual populations.
  2. Integration of predictive personalised pharmacokinetics into in-silico medicine research via individualised computer modelling.
  3. Assessment of the effects of drugs in validated, anatomically-based multi-scale predictive cardiac models for healthy and patient-specific disease conditions.
  4. Identification of selective and specific biomarkers to improve prediction of drug efficacy and safety.

Ischemia simulation @UPV

Demonstration of simulation of drug effects in cellular and 3D models

This is a recorded video showing the simulation workflow of SimCardioTest Use Case 3 (UC3) to assess drug effects by means of illustrative examples. This demo shows the main characteristics of each model integrating the workflow and the main simulation outputs used to evaluate drug safety and efficacy.